Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pilavapadin + semaglutide
- Development stage
- Unknown
- Lead developer
- Lexicon Pharmaceuticals
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
Pilavapadin + semaglutide is an investigational, preclinical combination therapy pairing Lexicon Pharmaceuticals' pilavapadin (LX9211, BMS-986176) with semaglutide. Pilavapadin is an oral, once-daily, selective small-molecule inhibitor of adapter protein-2–associated kinase 1 (AAK1), originally discovered in a neuroscience drug discovery alliance between Lexicon and Bristol Myers Squibb. Semaglutide is a marketed glucagon-like peptide-1 (GLP-1) receptor agonist peptide drug developed by Novo Nordisk. In preclinical mouse models of obesity, the combination of pilavapadin and semaglutide demonstrated synergistic weight loss efficacy, reducing body weight by 31% after 28 days of treatment compared to 25% for semaglutide alone and 14% for pilavapadin monotherapy. The combination is being explored for the treatment of obesity.
- Other names
- BMS-986176 + semaglutideBMS-986176 and semaglutideBMS986176 and semaglutideBMS 986176 and semaglutideLX9211 + semaglutideLX9211 and semaglutideLX-9211 and semaglutideLX 9211 and semaglutidepilavapadin and semaglutidesemaglutide + BMS-986176semaglutide + LX9211semaglutide + pilavapadinsemaglutide and BMS-986176semaglutide and LX9211semaglutide and pilavapadin
02
Targets
AAK1 (Adaptor-associated kinase 1)GLP1R (GLP-1R)
Beyond the preview
Go deeper on pilavapadin + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pilavapadin + semaglutide.